全文获取类型
收费全文 | 9975244篇 |
免费 | 651984篇 |
国内免费 | 155778篇 |
专业分类
耳鼻咽喉 | 130471篇 |
儿科学 | 281387篇 |
妇产科学 | 232080篇 |
基础医学 | 1238216篇 |
口腔科学 | 263919篇 |
临床医学 | 1007629篇 |
内科学 | 1662961篇 |
皮肤病学 | 203351篇 |
神经病学 | 722221篇 |
特种医学 | 375675篇 |
外国民族医学 | 1671篇 |
外科学 | 1323032篇 |
综合类 | 706060篇 |
现状与发展 | 513篇 |
一般理论 | 3730篇 |
预防医学 | 793974篇 |
眼科学 | 228309篇 |
药学 | 859951篇 |
2723篇 | |
中国医学 | 209182篇 |
肿瘤学 | 535951篇 |
出版年
2022年 | 80598篇 |
2021年 | 179004篇 |
2020年 | 141700篇 |
2019年 | 145348篇 |
2018年 | 177400篇 |
2017年 | 157967篇 |
2016年 | 151927篇 |
2015年 | 189236篇 |
2014年 | 277428篇 |
2013年 | 369337篇 |
2012年 | 522042篇 |
2011年 | 566721篇 |
2010年 | 383653篇 |
2009年 | 345043篇 |
2008年 | 482566篇 |
2007年 | 503089篇 |
2006年 | 480459篇 |
2005年 | 442662篇 |
2004年 | 389668篇 |
2003年 | 360554篇 |
2002年 | 331891篇 |
2001年 | 311763篇 |
2000年 | 309760篇 |
1999年 | 263611篇 |
1998年 | 103411篇 |
1997年 | 90369篇 |
1996年 | 84401篇 |
1995年 | 83253篇 |
1994年 | 75588篇 |
1993年 | 64738篇 |
1992年 | 182732篇 |
1991年 | 177035篇 |
1990年 | 171586篇 |
1989年 | 166529篇 |
1988年 | 153880篇 |
1987年 | 149937篇 |
1986年 | 142821篇 |
1985年 | 136065篇 |
1984年 | 103443篇 |
1983年 | 88637篇 |
1982年 | 56308篇 |
1979年 | 92739篇 |
1978年 | 66523篇 |
1977年 | 57228篇 |
1976年 | 53103篇 |
1975年 | 58200篇 |
1974年 | 67246篇 |
1973年 | 64180篇 |
1972年 | 59385篇 |
1971年 | 54994篇 |
排序方式: 共有10000条查询结果,搜索用时 22 毫秒
61.
目的:分析子野个数限值对宫颈癌固定野调强放疗(fixed-field intensity-modulated radiotherapy,ff-IMRT)计划的影响,寻求最优的子野个数限值。方法:选取10例接受ff-IMRT的宫颈癌患者,基于Monaco 5.11.03计划系统,以45 Gy/25 f处方剂量分别对同一患者设计8种ff-IMRT计划(ff-IMRT计划依据子野个数限值命名,子野个数限值分别为40、60、70、80、100、120、130、150),采用SPSS 20.0软件比较除plan100之外7个ff-IMRT计划与plan100剂量学参数、优化时间和治疗参数的差异。结果:8种ff-IMRT计划归一化后,plan40和plan60的D2%、Dmin、CI和HI均劣于plan100(P<0.05)。8种ff-IMRT计划均能较好保护危及器官(organ at risk,OAR)和正常组织。plan40小肠V45;plan40和plan60小肠D2cc,直肠、膀胱V45、D40%,两侧股骨头V40和正常组织 V35、V40均高于plan100(P<0.05)。plan40和plan60优化时间、治疗参数均优于plan100(P<0.05);plan120、plan130和plan150子野面积、子野个数(51~150 cm2和>150 cm2)和出束时间均劣于plan100(P<0.05)。结论:子野个数限值为70~100时,ff-IMRT计划能兼顾剂量学参数满足临床要求、优化时间和治疗参数最优化,建议在设计宫颈癌ff-IMRT计划时在该范围内设置子野个数限值。 相似文献
62.
63.
64.
65.
66.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
67.
Rozhkov V. P. Trifonov M. I. Soroko S. I. 《Neuroscience and behavioral physiology》2022,52(3):383-394
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia... 相似文献
68.
69.
Wan-Jun Zhang Li-Qiang Wu Jun Wang Sheng-Yun Lin Bo Wang 《World Journal of Clinical Cases》2022,10(23):8242-8248
ABSTRACT
BACKGROUND
Hepatitis-associated aplastic anemia (HAAA) is a rare condition. Patients with HAAA usually present with acute hepatitis, jaundice and significantly increased transaminase. After 1–2 mo, hepatitis gradually improves, but progressive hemocytopenia, bone marrow hematopoietic failure, and severe or extremely severe aplastic anemia are manifest. Most cases of HAAA are fulminant and usually lethal if left untreated. The literature on Epstein–Barr virus (EBV)-associated HAAA is sparse.
CASE SUMMARY
We report a 30-year-old man who was admitted to our hospital because of pale yellow urine and skin with a simultaneous decrease in peripheral blood ternary cells. We made a diagnosis of EBV-associated HAAA. The treatment strategy for this patient included eltrombopag, an immunosuppressive regimen of rabbit anti-human thymocyte immunoglobulin, cyclosporine, and supportive care. The patient was discharged in normal physical condition after five months. A hemogram performed on follow-up revealed that he had achieved a complete response.
CONCLUSION
Eltrombopag plus anti-thymocyte globubin and cyclosporine may be a therapeutic option for EBV-associated HAAA.Larger studies are warranted to confirm. 相似文献
70.